Boyer 1998.

Methods	Twenty‐six‐week double‐blind, randomised, multicentre study
Participants	Outpatients (primary care) fulfilling DSM‐IV criteria for major depressive disorder, with a score of at least 20 at Montgomery and Asberg Scale for Depression (MADRS). Age range: 18‐65 years Exclusion criteria: pregnancy, lactation, failure to use a safe contraceptive method; concurrent major psychiatric disorders, such as anxiety disorder, dementia, somatoform disorders, agoraphobia, social phobia, any history of schizophrenia, psychosis or personality disorder; severe concurrent medical illness; alcohol or drug dependence; serious adverse reactions related to medicines; previous treatment with antidepressant for less than 3 week; major suicide risk.
Interventions	Fluoxetine: 120 participants Sertraline: 122 participants Fluoxetine dose range: 20‐60 mg/day Sertraline dose range: 50‐150 mg/day
Outcomes	MADRS and Clinical Global Impression (CGI)
Notes	Response: decrease of at least 50% in the MADRS total score Funding: by industry
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further information
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Double blind, no further information
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double blind, no further information
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Double blind, no further information
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Criteria and number of drop‐out reported. Rating scale reported without denominator
Selective reporting (reporting bias)	Unclear risk	Scores at rating scales were reported without standard deviations. Side effects reported
Other bias	High risk	Last author's affiliation was Pfizer France, Orsay. This company produces sertraline